Halozyme Therapeutics Files 8-K on Security Holder Vote
Ticker: HALO · Form: 8-K · Filed: May 2, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | May 2, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: HALO
TL;DR
HALO shareholders voted on something May 1st, details TBD.
AI Summary
On May 1, 2025, Halozyme Therapeutics, Inc. filed an 8-K report indicating that matters were submitted to a vote of security holders. The filing does not disclose the specific proposals voted on or the outcome of the vote.
Why It Matters
This filing signals that important corporate decisions requiring shareholder approval have been put to a vote, which could impact the company's future direction.
Risk Assessment
Risk Level: low — The filing is a routine procedural report and does not contain new financial information or significant operational changes.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- May 1, 2025 (date) — Date of Earliest Event Reported
- 001-32335 (other) — Commission File Number
- Delaware (other) — State of Incorporation
- 88-0488686 (other) — I.R.S. Employer Identification No.
- 12390 El Camino Real (address) — Principal Executive Offices
- San Diego (location) — City of Principal Executive Offices
- California (location) — State of Principal Executive Offices
- 92130 (other) — Zip Code of Principal Executive Offices
- ( 858 ) 794-8889 (phone_number) — Registrant's telephone number
FAQ
What specific matters were submitted to a vote of Halozyme Therapeutics, Inc. security holders on May 1, 2025?
The filing states that matters were submitted to a vote of security holders, but does not specify what those matters were.
What was the outcome of the vote by Halozyme Therapeutics, Inc. security holders?
The 8-K filing does not disclose the results or outcome of the vote.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this filing occurred on May 1, 2025.
What is Halozyme Therapeutics, Inc.'s principal executive office address?
The principal executive offices are located at 12390 El Camino Real, San Diego, California 92130.
What is Halozyme Therapeutics, Inc.'s telephone number?
The registrant's telephone number is (858) 794-8889.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 2, 2025 regarding HALOZYME THERAPEUTICS, INC. (HALO).